What is the role of denosumab in bone health management of breast cancer?

Updated: Nov 06, 2019
  • Author: Winston W Tan, MD, FACP; Chief Editor: Marie Catherine Lee, MD, FACS  more...
  • Print


In September 2011, denosumab (Prolia) was approved by the U.S. Food and Drug Administration (FDA) to increase bone mass in women at high risk for fracture who are receiving adjuvant aromatase inhibitor therapy for breast cancer. A dose of 60 mg is administered subcutaneously every 6 months.

Denosumab is a fully human monoclonal antibody that targets the receptor activator of the nuclear factor-kappa-B ligand (RANKL), which acts as the primary signal to promote bone removal. By inhibiting the development and activity of osteoclasts, denosumab decreases bone resorption and increases bone density.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!